-
Company Insights
New![]()
Innovation and Patenting activity of Arcturus Therapeutics Holdings Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Arcturus Therapeutics Holdings Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
New![]()
Net Present Value Model: Arcturus Therapeutics Holdings Inc’s ARCT-810
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ARCT-810 in Ornithine-Transcarbamylase Deficiency
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ARCT-810 in Ornithine-Transcarbamylase Deficiency Drug Details: ARCT-810 is under development for the treatment of ornithine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BSI-060T in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BSI-060T in Colorectal Cancer Drug Details: BSI-060T is under development for the treatment of solid...
-
Sector Analysis
![]()
COVID-19 Vaccines Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2026
COVID-19 Vaccines Market Report Overview The sales of COVID-19 vaccines across the 7MM reached $25 billion in 2021 and consisted of Tour authorized products: Comirnaty, Spikevax, Vaxzevria, and Jcovden. the COVID-19 vaccines market declined across the 7MM in 2022 as most individuals completed primary vaccinations and received at least one dose of an updated bivalent mRNA booster vaccine. Overall, the COVID-19 vaccines market is expected to significantly decline across the 7MM during the forecast period, at a negative compound annual...
-
Company Profile
![]()
Arcturus Therapeutics Holdings Inc – Company Profile
Arcturus Therapeutics Holdings Inc (Arcturus) formerly Arcturus Therapeutics Ltd, is a pharmaceutical company that develops a portfolio of nucleic acid therapeutics for treatment of diseases. The company discovers and develops RNA medicines and design and utilize lipid-mediated drug delivery systems. Arcturu’s pipeline products portfolio include ARCT-810 (LUNAR-OTC), ARCT-032 (LUNAR-CF), ARCT-021 (LUNAR-COV19 Vaccine) and LUNAR Flu. It provides messenger RNA (mRNA), that is used as protein replacement therapy to treat diseases caused by a lack of protein and by defective proteins...
Add to Basket -
Product Insights
![]()
Fragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Fragile X Syndrome Clinical Trials Market Report Overview The Fragile X Syndrome clinical trial market research report provides an overview of the Fragile X Syndrome clinical trials scenario. The report provides top-line data relating to the clinical trials on Fragile X Syndrome. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Sector Analysis
![]()
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
![]()
Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ornithine transcarbamylase (OTC Deficiency) deficiency is a rare X-linked genetic disorder characterized by complete or partial lack of the enzyme ornithine transcarbamylase (OTC Deficiency). OTC Deficiency plays an important role in the break down and removal of nitrogen in the body (urea cycle). The lack of the OTC Deficiency enzyme results in excessive accumulation of nitrogen, in the form of ammonia (hyperammonemia), in the blood. Symptoms include vomiting, refusal to eat, progressive lethargy, and coma. The Ornithine-Transcarbamylase (OTC Deficiency) Deficiency...
-
Track & Monitor
![]()
Pharmaceuticals Industry Deals and Trends in November 2022 – Partnerships, Licensing, Investments, Mergers and Acquisitions (M&A)
Pharmaceuticals Industry Deals and Trends Report Overview The pharmaceutical and healthcare market reported 418 deals worth $43.8 billion in November 2022. The market registered an increase in the number of mergers and acquisitions (M&As) including asset purchases and a decrease in their deal values in November 2022. Â Capital raising, through equity and debt offerings, reported an increase in the number of deals and in deal values. The Pharmaceuticals Industry Deals and Trends report provides detailed information on partnership and licensing...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.